Parkinson's Disease - Molecular Basis for Cognitive Impairment
The Molecular Basis for Cognitive Impairment in Parkinson's Disease (GAC 0156)
Protocol ID
06-108T
Protocol Description
The purpose of this study is to measure different types of brain function in patients with Parkinson's disease (PD).
Eligibility Criteria
Patients with Parkinson's disease (PD)
Primary Investigator(s)
- Andrew Feigin, MD
Contact Information
Last Update
April 12, 2010How did I get to this page?
Related Information
-
News Room
- Feinstein Researchers Uncover Genetic Risk for Schizophrenia
- Lancet Study Shows Gene Therapy for Parkinson's Disease is Safe and Some Patients Benefit
- Scientists Identify Two Distinct Parkinson's Networks
- PET Scans Show Gene Therapy Normalizes Brain Function in Parkinson's Patients
- Second Annual Brain Aneurysm Awareness Walk to be Held Oct. 2 at Jones Beach
- Feinstein Institute Becomes Home to Prestigious Federally-Funded Center on Parkinson’s Disease
- Feinstein Institute, Thomas Hartman Foundation for Parkinson’s Research, Sign Affiliation Agreement
-
Clinical Trials
- Movement Disorders - Functional Correlates Study (08-191)
- Brain and Behavior in Dystonia: A Multicenter Study (03.02.079G)
- Multiple Sclerosis - Diffusion Tensor MRI Correlates of Depression (03.02.084T)
- Laparoscopic Experience and Functional Brain Activation (07-106)
- Schizophrenia - Functional MRI of Medication Effects (02.04.030)
- Systemic Lupus Erythematosus - PET/MRI Study (07-012)
- Epilepsy - Cognitive and Sensorimotor Study (07-125)
- Brain Networks in Parkinson's Disease (04-113T)
- Parkinson's Disease Genetics Database (07-057)
- REM Behavior Disorder and Parkinsonism: Longitudinal PET Study (08-126)
- Neuroendocrine Tumors - Imaging Study (03-117)
- Parkinson’s Disease - Early Differential Diagnosis of Parkinsonism with Metabolic Imaging and Pattern Analysis
- Schizophrenia - Genetic Study (08-252)
- Brain and Behavior in Dystonia Study (08-283)
- Cannabis - Dopamine Study - (09-002)
- Huntington's Disease - Clinical Trial (09-012)
- Psychosis - PET Study (09-037)
- Schizophrenia-like Effects of Cannibinoids (09-157)
- Web-delivery Treatment for Substance Abuse (10-016A)
- Parkinson’s Disease - Microvascular Changes in Parkinson’s Disease: Relationship to Levodopa-Induced Dyskinesia
- Parkinson’s Disease - Metabolic Networks and the Cognitive Treatment Response in Parkinson’s Disease
General Navigation
Persistent Navigation
-
Clinical Trials
- Addiction
- Aging
- Allergies
- Arthritis
- Autoimmune Disease
- Blood Disorders
- Cancer
- Children's Health
- Circulation
- Dental
- Diabetes
- Ear & Hearing
- Eyes
- Gastrointestinal/Hepatitis
- Genetics
- Heart
- HIV
- Infectious Diseases
- Joints
- Kidney
- Lung
- Lupus
- Men's Health
- Mental Health
-
Neurosciences
- Alzheimer's Disease - Memantine Study (06.02.108T)
- Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment and at Six Month Follow-up (11-196A)
- Autism Spectrum Disorders - Adult Study (07.04.051)
- Brain and Behavior in Dystonia: A Multicenter Study (03.02.079G)
- Brain and Behavior in Dystonia Study (08-283)
- Brain AVM - Clinical Trial (06.02.063)
- Brain Networks in Parkinson's Disease (04-113T)
- Cannabis - Dopamine Study - (09-002)
- Clinical Correlates of Memory Impairment (03.08.160)
- Dementia - Clinical Trial (08-295)
- Dystonia - Deep Brain Stimulation Study (06-109T)
- Epilepsy
- Epilepsy - Cognitive and Sensorimotor Study (07-125)
- Epilepsy - Genetic Marker and Enzyme Study (07.08.009)
- Epilepsy - Multicenter Study (06.08.058)
- Glioblastoma - Clinical Trial (08-06-234)
- Huntington's Disease - Clinical Trial (09-012)
- Huntington's Disease - Coenzyme Q10 Study (07-124)
- Laparoscopic Experience and Functional Brain Activation (07-106)
- Memory Disorders Study (08-219)
- Metastatic Brain Tumor Study (08-10-24)
- MIF - Spinal Cord Injury Study (09-026)
- Movement Disorders - Functional Correlates Study (08-191)
- Multiple Sclerosis - Diffusion Tensor MRI Correlates of Depression (03.02.084T)
- Neuroendocrine Tumors - Imaging Study (03-117)
- Parkinson's Disease Genetics Database (07-057)
- Parkinson's Disease - Genetic Study (07-058)
- Parkinson's Disease - Molecular Basis for Cognitive Impairment (06-108T)
- Parkinson's Disease - Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel (B09-004)
- Parkinson’s Disease - Early Differential Diagnosis of Parkinsonism with Metabolic Imaging and Pattern Analysis
- Parkinson’s Disease - Efficacy, Safety, and Tolerability of Pioglitazone
- Parkinson’s Disease - Efficacy, Safety and Tolerability of CoganeTM (B10-046)
- Parkinson’s Disease - Efficacy and Safety of Sufinamide (B10-026)
- Parkinson’s Disease - Efficacy and Safety Study of Low and High Doses of Safinamide (10-02-48-031)
- Parkinson’s Disease - Metabolic Networks and the Cognitive Treatment Response in Parkinson’s Disease
- Parkinson’s Disease - Microvascular Changes in Parkinson’s Disease: Relationship to Levodopa-Induced Dyskinesia
- Parkinson’s Disease - Open-Label Continuation Treatment Study with Levodopa-Carbidopa Intestinal Gel (B10-039)
- Pitch Recognition in Autistic Spectrum Disorders (04-053)
- REM Behavior Disorder and Parkinsonism: Longitudinal PET Study (08-126)
- Schizophrenia-like Effects of Cannibinoids (09-157)
- Swallowing Therapy Study (07-130)
- Web-delivery Treatment for Substance Abuse (10-016A)
- Recruitment Registry
- Skin
- Sleep Disorders
- Smoking
- Urinary Tract
- Weight Control
- Women's Health